Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Madar, Shalom ^a   Harel, Einav ^a   Goldstein, Ido ^a   Stein, Yan ^a   Kogan Sakin, Ira ^a   Kamer, Iris ^a   Solomon, Hilla ^a   Dekel, Elya ^a   Tal, Perry ^a   Goldfinger, Naomi ^a   Friedlander, Gilgi ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; PHOSPHOPROTEIN; PROTEIN WIG1; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER IMMUNOLOGY; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; CYTOKINE RESPONSE; FIBROBLAST; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; LUNG CANCER; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; FIBROBLASTS; HUMANS; INTERFERON-BETA; LUNG NEOPLASMS; MUTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA STABILITY; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84876447018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061353     Document Type: Article

References (63)

1. Joyce JA, (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513-520.
2. Witz IP, (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2 Suppl 1: 9-17.
3. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
4. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, et al. (2011) Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 108: 7160-7165.
5. Zhao H, Ramos CF, Brooks JD, Peehl DM, (2007) Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol 210: 111-121.
6. Bauer EA, Uitto J, Walters RC, Eisen AZ, (1979) Enhanced collagenase production by fibroblasts derived from human basal cell carcinomas. Cancer Res 39: 4594-4599.
7. Rasmussen AA, Cullen KJ, (1998) Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 47: 219-233.
8. van den Hooff A, (1988) Stromal involvement in malignant growth. Adv Cancer Res 50: 159-196.
9. Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, et al. (2009) Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 30: 20-27.
10. Buganim Y, Madar S, Rais Y, Pomeraniec L, Harel E, et al. (2011) Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression. Carcinogenesis 32: 1749-1757.
11. Vousden KH, Prives C, (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
12. Solomon H, Madar S, Rotter V, (2011) Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 225: 475-478.
13. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, et al. (2010) p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70: 9650-9658.
14. Tian Y, Ding RY, Zhi YH, Guo RX, Wu SD, (2006) Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 12: 415-419.
15. Famulski W, Sulkowska M, Wincewicz A, Kedra B, Pawlak K, et al. (2006) P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 53: 43-48.
16. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, et al. (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16: 1086-1093.
17. Platanias LC, (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375-386.
18. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, et al. (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603.
19. Dunn GP, Koebel CM, Schreiber RD, (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
20. Tsai YC, Pestka S, Wang LH, Runnels LW, Wan S, et al. (2011) Interferon-beta signaling contributes to Ras transformation. PLoS One 6: e24291.
21. Tjandra SS, Hsu C, Goh YI, Gurung A, Poon R, et al. (2007) IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. Cancer Res 67: 7124-7131.
22. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523.
23. Chiantore MV, Vannucchi S, Accardi R, Tommasino M, Percario ZA, et al. (2012) Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS One 7: e36909.
24. Zhang F, Sriram S, (2009) Identification and characterization of the interferon-beta-mediated p53 signal pathway in human peripheral blood mononuclear cells. Immunology 128: e905-918.
25. Liu M, Tanswell AK, Post M, (1999) Mechanical force-induced signal transduction in lung cells. Am J Physiol 277: L667-683.
26. Sharan R, Maron-Katz A, Shamir R, (2003) CLICK and EXPANDER: a system for clustering and visualizing gene expression data. Bioinformatics 19: 1787-1799.
27. Sharan R, Shamir R, (2000) CLICK: a clustering algorithm with applications to gene expression analysis. Proc Int Conf Intell Syst Mol Biol 8: 307-316.
28. Ingenuity Website. Available: www.ingenuity.com. Accessed 2012Sep 1.
29. Buess M, Nuyten DS, Hastie T, Nielsen T, Pesich R, et al. (2007) Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol 8: R191.
30. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ, (2009) INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 37: D852-857.
31. Uze G, Schreiber G, Piehler J, Pellegrini S, (2007) The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
32. Hayashi T, Kaneda T, Toyama Y, Kumegawa M, Hakeda Y, (2002) Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 277: 27880-27886.
33. Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, et al. (2009) TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J Exp Med 206: 1863-1871.
34. Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, et al. (2009) Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer 125: 556-564.
35. Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, et al. (2009) Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J Biol Chem 284: 15206-15214.
36. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, et al. (2011) Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 18: 271-281.
37. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, et al. (2012) Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene.
38. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
39. Vilborg A, Glahder JA, Wilhelm MT, Bersani C, Corcoran M, et al. (2009) The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc Natl Acad Sci U S A 106: 15756-15761.
40. Vilborg A, Bersani C, Wickstrom M, Segerstrom L, Kogner P, et al. (2012) Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth. Cell Death Dis 3: e298.
41. Chang WL, Coro ES, Rau FC, Xiao Y, Erle DJ, et al. (2007) Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals. J Immunol 178: 1457-1467.
42. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, et al. (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65: 7573-7579.
43. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, et al. (1997) A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. Embo J 16: 4384-4392.
44. Varmeh-Ziaie S, Okan I, Wang Y, Magnusson KP, Warthoe P, et al. (1997) Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene 15: 2699-2704.
45. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, et al. (2008) Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 10: 450-461.
46. Vilborg A, Bersani C, Wilhelm MT, Wiman KG, (2011) The p53 target Wig-1: a regulator of mRNA stability and stem cell fate? Cell Death Differ 18: 1434-1440.
47. Ginsberg D, Michael-Michalovitz D, Oren M, (1991) Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol 11: 582-585.
48. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, et al. (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208: 469-478.
49. Erez N, Truitt M, Olson P, Arron ST, Hanahan D, (2010) Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 17: 135-147.
50. Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, et al. (2009) Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis 30: 698-705.
51. Mueller L, Goumas FA, Affeldt M, Sandtner S, Gehling UM, et al. (2007) Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol 171: 1608-1618.
52. Tjomsland V, Spangeus A, Valila J, Sandstrom P, Borch K, et al. (2011) Interleukin 1alpha sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13: 664-675.
53. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, et al. (2011) Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19: 257-272.
54. Giannoni E, Bianchini F, Calorini L, Chiarugi P, (2011) Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal 14: 2361-2371.
55. Robles AI, Harris CC, (2010) Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2: a001016.
56. Madar S, Stambolsky P, Rotter V, (2011) Unleash the wild type: restoration of p53 suppressive activity in skin cancer. Cell Cycle 10: 736-737.
57. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, et al. (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280: 30384-30391.
58. Foster BA, Coffey HA, Morin MJ, Rastinejad F, (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510.
59. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, et al. (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Molecular Cell 8: 781-794.
60. Wang BX, Rahbar R, Fish EN, (2011) Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res 31: 545-552.
61. Ozaki T, Nakagawara A, (2005) p73, a sophisticated p53 family member in the cancer world. Cancer Sci 96: 729-737.
62. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, et al. (2011) p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 30: 2670-2678.
63. Smyth GK, Speed T, (2003) Normalization of cDNA microarray data. Methods 31: 265-273.